Syndax Pharmaceuticals Inc (SNDX) stock
SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.20+0.07 (+0.77%)
Close on Nov 17, 2026Market cap $821.53MP/E –Yield –
Syndax Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Syndax Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $273.00M, up 11.1% year over year. For fiscal 2025 it was $258.78M, up 7.1% from the year before. Over ten years it grew 39.1% a year on average. The highest annual figure on record is $258.78M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.78M | +7.1% |
| FY2024 | Dec 31, 2024 | $241.65M | +48.2% |
| FY2023 | Dec 31, 2023 | $163.03M | +37.6% |
| FY2022 | Dec 31, 2022 | $118.50M | +34.3% |
| FY2021 | Dec 31, 2021 | $88.25M | +75.0% |
| FY2020 | Dec 31, 2020 | $50.44M | +17.3% |
| FY2019 | Dec 31, 2019 | $42.99M | -28.5% |
| FY2018 | Dec 31, 2018 | $60.11M | +24.7% |
| FY2017 | Dec 31, 2017 | $48.20M | +52.2% |
| FY2016 | Dec 31, 2016 | $31.67M | +231.6% |
| FY2015 | Dec 31, 2015 | $9.55M | -6.2% |
| FY2014 | Dec 31, 2014 | $10.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $67.48M | +19.9% |
| Q2 FY2026 | Jun 30, 2026 | $68.04M | +9.3% |
| Q1 FY2026 | Mar 31, 2026 | $58.85M | -4.5% |
| Q4 FY2025 | Dec 31, 2025 | $78.64M | +20.0% |
| Q3 FY2025 | Sep 30, 2025 | $56.28M | -20.7% |
| Q2 FY2025 | Jun 30, 2025 | $62.23M | +27.9% |
| Q1 FY2025 | Mar 31, 2025 | $61.64M | +9.1% |
| Q4 FY2024 | Dec 31, 2024 | $65.53M | +18.9% |
| Q3 FY2024 | Sep 30, 2024 | $70.97M | +81.6% |
| Q2 FY2024 | Jun 30, 2024 | $48.66M | +40.0% |
| Q1 FY2024 | Mar 31, 2024 | $56.49M | +65.9% |
| Q4 FY2023 | Dec 31, 2023 | $55.13M | +73.1% |
| Q3 FY2023 | Sep 30, 2023 | $39.09M | +45.3% |
| Q2 FY2023 | Jun 30, 2023 | $34.76M | +16.9% |
| Q1 FY2023 | Mar 31, 2023 | $34.05M | +13.4% |
| Q4 FY2022 | Dec 31, 2022 | $31.84M | +33.2% |
| Q3 FY2022 | Sep 30, 2022 | $26.90M | +5.1% |
| Q2 FY2022 | Jun 30, 2022 | $29.73M | +76.2% |
| Q1 FY2022 | Mar 31, 2022 | $30.02M | +37.3% |
| Q4 FY2021 | Dec 31, 2021 | $23.90M | +54.0% |
| Q3 FY2021 | Sep 30, 2021 | $25.61M | +77.7% |
| Q2 FY2021 | Jun 30, 2021 | $16.87M | +54.2% |
| Q1 FY2021 | Mar 31, 2021 | $21.87M | +128.7% |
| Q4 FY2020 | Dec 31, 2020 | $15.52M | +63.4% |
| Q3 FY2020 | Sep 30, 2020 | $14.41M | +45.2% |
| Q2 FY2020 | Jun 30, 2020 | $10.94M | -11.0% |
| Q1 FY2020 | Mar 31, 2020 | $9.56M | -15.2% |
| Q4 FY2019 | Dec 31, 2019 | $9.50M | -39.9% |
| Q3 FY2019 | Sep 30, 2019 | $9.92M | -29.6% |
| Q2 FY2019 | Jun 30, 2019 | $12.29M | -17.2% |
| Q1 FY2019 | Mar 31, 2019 | $11.28M | -26.5% |
| Q4 FY2018 | Dec 31, 2018 | $15.82M | -4.7% |
| Q3 FY2018 | Sep 30, 2018 | $14.10M | +15.6% |
| Q2 FY2018 | Jun 30, 2018 | $14.85M | +50.6% |
| Q1 FY2018 | Mar 31, 2018 | $15.34M | +60.6% |
| Q4 FY2017 | Dec 31, 2017 | $16.60M | +95.9% |
| Q3 FY2017 | Sep 30, 2017 | $12.19M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.86M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.47M | – |
See a number that looks wrong?